As Morgan Stanley pointed out, back in May 2019 J & J provided 2023 guidance of over $50 billion for its pharma business. To be fair, this isn't the first time the company issued a medium-term pharmaceutical revenue target that the Wall Street consensus did not initially believe in. The analysts asked whether J & Js long-term 2025 goal of $60 billion in pharmaceutical sales might be under threat. The concern is around expected slower growth for a key drug, Stelara - an immunosuppressive treatment for conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis - due to competition from generics. During Monday's "Morning Meeting" for members, Jim Cramer said that J & J has the "best balance sheet in America." Morgan Stanley's note In a research note last week, Morgan Stanley posed a series of thought-provoking questions about the pending split and what the business might look like afterward. For the Club, we consider Johnson & Johnson one of our 10 core holdings and believe the separation will sharpen the focus at both companies, allowing management at each to do what's best for their respective businesses, unlocking more shareholder value without worrying about the impact on the whole behemoth. Ahead of the split, Morgan Stanley put out a research note, highlighting some of the debates in the market over the move, which would result in a consumer brands company called Kenvue and a pharma company with the J & J moniker. Johnson & Johnson (JNJ) is preparing next year to spin off its consumer health unit into a publicly traded company separate from its pharmaceutical and medical technology operations. Personal Loans for 670 Credit Score or Lower Personal Loans for 580 Credit Score or Lower Best Debt Consolidation Loans for Bad Credit
0 Comments
Leave a Reply. |